Cargando…

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials

Pharmacogenomic (PGx) testing has emerged as a compelling strategy that clinicians can use to inform antidepressant medication selection and dosing, but the clinical efficacy of this strategy has been questioned. We systematically reviewed and meta‐analyzed clinical trials for an association between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Lisa C., Stanton, Joseph D., Bharthi, Kanika, Maruf, Abdullah Al, Müller, Daniel J., Bousman, Chad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827897/ https://www.ncbi.nlm.nih.gov/pubmed/36111494 http://dx.doi.org/10.1002/cpt.2748

Ejemplares similares

Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta Hospitals
por: Hayashi, Meagan, et al.
Publicado: (2022)

The Potential Roles of Pharmacists in the Clinical Implementation of Pharmacogenomics
por: Maruf, Abdullah Al, et al.
Publicado: (2023)

Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis
por: Stein, Kiera, et al.
Publicado: (2021)

Editorial: Pharmacogenomics: From Bench to Bedside and Back Again
por: Shaman, Jeffrey A., et al.
Publicado: (2022)

CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, Australia
por: Forbes, Malcolm, et al.
Publicado: (2023)

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
por: Bousman, Chad A., et al.
Publicado: (2017)

Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review
por: Brown, Lisa C., et al.
Publicado: (2023)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
por: Saya, Sibel, et al.
Publicado: (2023)

Pharmacogenomics in depression and antidepressants
por: Bondy, Brigitta
Publicado: (2005)

Partial remission, residual symptoms, and relapse in depression
por: Paykel, E.S.
Publicado: (2008)

Serotonin transporter polymorphism (5HTTLPR), severe childhood abuse and depressive symptom trajectories in adulthood
por: Nguyen, Timothy B., et al.
Publicado: (2015)

Development and remission of depressive symptoms and treatment with hormonal contraceptives
por: Nygaard Andersen, Mette, et al.
Publicado: (2014)

The role of cognitive dysfunction in the symptoms and remission from depression
por: Gonda, Xenia, et al.
Publicado: (2015)

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis
por: Islam, Farhana, et al.
Publicado: (2022)

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Moderates the Effects of Childhood Abuse on Severity of Depressive Symptoms in a Time-Dependent Manner
por: Webb, Caitlin, et al.
Publicado: (2016)

Pharmacogenomic Testing for Major Depression: A Qualitative Study of the Perceptions of People with Lived Experience and Professional Stakeholders
por: Slomp, Caitlin, et al.
Publicado: (2022)

Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis
por: Dawson, Marliese Y, et al.
Publicado: (2004)

Psychiatric pharmacogenomic testing in clinical practice
por: Mrazek, David A.
Publicado: (2010)

Overview of pharmacogenomic testing in clinical practice
por: Gross, Tonya, et al.
Publicado: (2018)

Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study
por: Montoya, Alonso, et al.
Publicado: (2016)

Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy
por: Roosan, Don, et al.
Publicado: (2020)

Patient Perspectives of Barriers and Facilitators for the Uptake of Pharmacogenomic Testing in Veterans Affairs’ Pharmacogenomic Testing for the Veterans (PHASER) Program
por: Melendez, Karina, et al.
Publicado: (2023)

A Comparison of Association Methods for Cytotoxicity Mapping in Pharmacogenomics
por: Brown, Chad, et al.
Publicado: (2011)

Pharmacogenomic Markers of Glucocorticoid Response in The Initial Phase of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2018)

Family History of Lung Cancer and Contemplation of Smoking Cessation
por: Madlensky, Lisa, et al.
Publicado: (2010)

Encountering Pharmacogenetic Test Results in the Psychiatric Clinic
por: Bousman, Chad A, et al.
Publicado: (2021)

The pharmacogenomics of pain management: prospects for personalized medicine
por: Ting, Sonya, et al.
Publicado: (2016)

Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
por: Vuic, Barbara, et al.
Publicado: (2023)

Public Attitudes toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota
por: Zhang, Lusi, et al.
Publicado: (2022)

Using a pharmacogenomic algorithm to guide the treatment of depression
por: Hall-Flavin, D K, et al.
Publicado: (2012)

Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT
por: Wang, Xinrui, et al.
Publicado: (2023)

Persistence and remission of depressive symptoms and psycho-social correlates in Chinese early adolescents
por: Chi, Xinli, et al.
Publicado: (2020)

Remission of symptoms is not equal to functional recovery: Psychosocial functioning impairment in major depression
por: Yang, Hao, et al.
Publicado: (2022)

Updating the landscape of direct-to-consumer pharmacogenomic testing
por: Filipski, Kelly K, et al.
Publicado: (2017)

Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges
por: Hippman, Catriona, et al.
Publicado: (2019)

Pharmacogenomic testing and antidepressant response: problems and promises
por: Smith, Tawny L., et al.
Publicado: (2020)

Adoption of Pharmacogenomic Testing: A Marketing Perspective
por: Koufaki, Margarita-Ioanna, et al.
Publicado: (2021)

Pharmacogenomic testing in paediatrics: Clinical implementation strategies
por: Barker, Charlotte I. S., et al.
Publicado: (2022)

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial
por: Tiwari, Arun K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qtb7bf5sd175p3ldtngr8j1i9s